| First Author | Ku B | Year | 2024 |
| Journal | Cell Rep Med | Volume | 5 |
| Issue | 3 | Pages | 101461 |
| PubMed ID | 38460517 | Mgi Jnum | J:346858 |
| Mgi Id | MGI:7619154 | Doi | 10.1016/j.xcrm.2024.101461 |
| Citation | Ku B, et al. (2024) PRMT1 promotes pancreatic cancer development and resistance to chemotherapy. Cell Rep Med 5(3):101461 |
| abstractText | Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal types of cancer, and novel treatment regimens are direly needed. Epigenetic regulation contributes to the development of various cancer types, but its role in the development of and potential as a therapeutic target for PDAC remains underexplored. Here, we show that PRMT1 is highly expressed in murine and human pancreatic cancer and is essential for cancer cell proliferation and tumorigenesis. Deletion of PRMT1 delays pancreatic cancer development in a KRAS-dependent mouse model, and multi-omics analyses reveal that PRMT1 depletion leads to global changes in chromatin accessibility and transcription, resulting in reduced glycolysis and a decrease in tumorigenic capacity. Pharmacological inhibition of PRMT1 in combination with gemcitabine has a synergistic effect on pancreatic tumor growth in vitro and in vivo. Collectively, our findings implicate PRMT1 as a key regulator of pancreatic cancer development and a promising target for combination therapy. |
